Phaeophyceae, commonly known as brown algae or seaweeds (such as Laminaria or Ascophyllum nodosum), have been studied for their potential hypolipidemic effects, including the reduction of high triglyceride levels. The primary bioactive compounds of interest are fucoxanthin (a carotenoid) and alginates, both found in various species of brown seaweed. Several animal studies and a limited number of small-scale human trials indicate that consumption of brown seaweed extracts can lead to modest reductions in blood triglyceride levels. The proposed mechanisms involve the inhibition of lipid absorption, modulation of lipid metabolism, and increased fatty acid oxidation, mainly attributed to fucoxanthin. For example, a 2010 randomized controlled trial in overweight Japanese adults found that fucoxanthin supplementation led to a significant decrease in serum triglyceride levels compared to placebo. However, the overall quality and quantity of clinical evidence remain limited, with most studies being preliminary, having small sample sizes, or lacking long-term follow-up. There is not yet robust, high-quality evidence to support routine clinical use of Phaeophyceae for hypertriglyceridemia, but the scientific rationale and early data justify further investigation. Traditional uses for this indication are not well documented, so its use is primarily based on emerging scientific research rather than historical precedent.